Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.
US RNA aptamers for type 1 diabetes and tumours — NIDDK/NCI fit.
Evidence from the records
- “"Biotech & life sciences"”
- “RNA aptamers – type 1 diabetes and solid tumors”
- “No public evidence of traction found: preclinical RNA aptamer pipeline.”
- Intro path
- Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
- First step
- Prepare SBIR Phase I.